| Literature DB >> 33684524 |
Xin Li1, Boer Li2, Yu Shi1, Chenglin Wang2, Ling Ye3.
Abstract
Reactive oxygen species (ROS) have emerged as key players in regulating the fate and function of stem cells from both non-hematopoietic and hematopoietic lineages in bone marrow, and thus affect the osteoblastogenesis-osteoclastogenesis balance and bone homeostasis. Accumulating evidence has linked ROS and associated oxidative stress with the progression of bone disorders, and ROS-based therapeutic strategies have appeared to achieve favorable outcomes in bone. We review current knowledge of the multifactorial roles and mechanisms of ROS as a target in bone pathology. In addition, we discuss emerging ROS-based therapeutic strategies that show potential for bone therapy. Finally, we highlight the opportunities and challenges facing ROS-targeted stem cell therapeutics for improving bone health.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33684524 DOI: 10.1016/j.drudis.2021.03.002
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851